{
  "trial_id": "NCT03952637",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age at time of full ICF signing",
      "label": "met",
      "evidence": "6 months old and les than or equal to 12 months old"
    },
    {
      "criterion": "Biallelic mutations in GLB1",
      "label": "met",
      "evidence": "Documented deficiency of Beta-galactosidase enzyme by clinical laboratory testing"
    },
    {
      "criterion": "Phenotype consistent with a diagnosis of Type I GM1 gangliosidosis",
      "label": "met",
      "evidence": "Symptomatic subjects: as determined by the opinion of the Principal Investigator"
    }
  ],
  "exclusion": [
    {
      "criterion": "AAV9 antibody titers >1:50",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Pregnant or lactating subjects",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "Patient has a history of viral encephalitis/meningitis-->ICH-->seizure/stroke and CSF leak w/ meningitis s/p lumbar drain placement, but these conditions do not appear to be relevant to the trial.",
  "_meta": {
    "topic_id": "4",
    "trial_id": "NCT03952637",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}